ulcerative colitis

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.

Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.

Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.